Intuitive Surgical ISRG

Reference table

1. What the business is, and why the revenue mix is the moat

Chief executive David J. Rosa; approximately 17,021 employees. Intuitive reports one segment and discloses revenue by type — and that disclosure is the investment case.

Instruments and accessories plus services — the recurring half — is $7,591.0 million, 75.4% of revenue, and it grew 39.4% over two years. Systems, the lumpy capital-equipment line, is 24.6%. A company where three-quarters of revenue is consumed rather than sold does not have the cyclicality of a capital-equipment business, and it explains why the operating margin has risen from 24.1% (FY2020) to 29.3% (FY2025) and 33.6% in the most recent quarter.

Geography, from seg_geo, which reconciles exactly:

Two-thirds of revenue is United States, and the United States is the slower-growing half — 12% procedure growth against 20% outside it. That mix is the medium-term opportunity and the near-term drag simultaneously.

The installed base, from the 10-Q at 2026-06-30, and this is the compounding asset:

• da Vinci 5 — the fifth-generation multi-port system, FDA-cleared March 2024: 1,710 systems installed, of which only 136 are outside the United States. Regulatory clearance in South Korea October 2024, Japan June 2025, and European certification under EU MDR July 2025 — so the international rollout is roughly one year old.
• da Vinci SP — the single-incision system, commercialised 2018: 445 systems. The 10-Q describes it as still "in the early stages of launching."
• Approximately 70 different multi-port instruments and 16 core single-port instruments, plus energy and stapler product lines.

The switching cost is not contractual, it is clinical. A surgeon trained on da Vinci, in a hospital that has built its theatre workflow around it, with a decade of outcome data behind those procedures, does not change platform because a competitor's list price is lower. That is why 75.4% of revenue recurs, and it is the single most durable feature of any business in this batch.

2. Procedure growth — the number the whole thesis turns on

From the 10-Q filed 2026-07-21, verbatim:

> "Total da Vinci procedures performed by our customers grew approximately 15% for the three months ended June 30, 2026, compared to approximately 17% for the three months ended June 30, 2025."

> "U.S. da Vinci procedures grew approximately 12% for the three months ended June 30, 2026, compared to approximately 14%... The second quarter 2026 U.S. procedure growth was largely attributable to strong growth in general surgery procedures, most notably cholecystectomy, hernia repair, and appendectomy procedures, as well as growth in gynecological procedures, partially offset by a high-single-digit decline in U.S. bariatric procedures, which comprise approximately 2% of our total da Vinci procedures. We believe that U.S. procedure growth was also modestly negatively impacted by the expiration of enhanced ACA premium subsidies. The extent of the continued impact of these expirations on U.S. procedure volumes remains uncertain."

> "OUS da Vinci procedures grew approximately 20% for the three months ended June 30, 2026, compared to approximately 23%... We saw strong procedure growth in India, Italy, and the United Kingdom during the second quarter of 2026."

Three observations, and the third is the one that matters most.

First, the deceleration is uniform. Every geography slowed by two to three points. This is not a single market failing; it is a global growth rate stepping down.

Second, the United States driver has changed. Growth is now coming from general surgery — cholecystectomy, hernia repair, appendectomy — rather than from urology and gynaecology, which were the original franchises. That is what a maturing adoption curve looks like: the high-value, high-penetration procedures are done, and growth moves to higher-volume, lower-complexity ones. The bariatric decline, on 2% of procedures, is a small negative. And the company names a policy driver — the expiration of enhanced ACA premium subsidies — whose continuing effect it says "remains uncertain."

Third, and this is the point: the outside-United-States rate of approximately 20% is running on an installed base of just 136 da Vinci 5 systems. European certification arrived in July 2025 and Japanese clearance in June 2025. The 32.3% of revenue that grows at 20% is doing so with the current-generation platform barely deployed. If the international rollout accelerates, the blended rate stabilises without the United States improving at all.

Management's own full-year guidance — management voice, half-weighted, and sourced from the knowledge base because the earnings 8-Ks in this archive are cover documents only: worldwide da Vinci procedure growth of approximately 13.5% to 15.5% for 2026. The June quarter came in at approximately 15%, at the top of that range.

3. The financials, and the drawdown they do not explain

Revenue has risen 130.9% in five years — 18.2% compound — and FY2025 accelerated to 20.5%. Gross margin has held in a 65.6-69.3% band. Operating margin has risen from 24.1% to 31.3% trailing. GAAP earnings per share have gone from $3.02 to $8.85.

The quarterly picture, which is even better:

Five consecutive beats, ranging from 11.5% to 20.6%, averaging +14.0%. The June 2026 quarter produced the highest gross margin (67.8%) and the highest operating margin (33.6%) in the entire file, on revenue up 18.5%.

This is the central puzzle of the name and it should be stated plainly: over the twelve months in which the share price fell 23.8%, the company beat consensus every quarter, grew revenue between 18% and 23%, and expanded its operating margin by more than three points. The de-rating is not about results. It is about the growth rate embedded in a multiple that had reached somewhere north of 60 times forward earnings, and about a procedure growth rate that stepped down two points.

4. Balance sheet and cash flow — no debt, and a buyback that has restarted

Total debt of $302.8 million against $9,233.4 million of cash and investments, on an $86.4% equity ratio. The vendor reports debtToEquityRatioTTM of exactly zero, which is a rounding of 0.017x rather than an error. Of the $302.8 million, $131.9 million is explicitly finance-lease obligations.

The enterprise-value rebuild, and here the vendor makes the standard omission:

> Market cap $130.100B

> + total debt $0.303B

> − cash $3.368B

> − short-term investments $2.567B

> = corrected enterprise value $124.468B

The vendor reports enterpriseValueTTM of $127.340B — market capitalisation plus debt less cash only, omitting the $2,566.9 million of short-term investments. A 2.3% overstatement. Counting the $3,298.5 million of long-term investments as well would give $121.169B, though we do not net long-term investments as a matter of course. We use $124.468B, giving EV/Sales of 11.3x against the vendor's 11.5x, and note that on the widest definition net cash is $8,930.6 million, 6.9% of the market capitalisation.

Cash flow, and the swing in FY2025 is worth explaining:

Free cash flow nearly doubled in FY2025 — from $1,303.8M to $2,490.7M — and roughly half the improvement is capital expenditure halving from $1,111.2M to $539.8M. That is the end of a manufacturing build-out, not an operating improvement, and it should not be extrapolated. capexToDepreciationTTM is 0.596, so capital spending is now running below depreciation.

The buyback restarted at scale: $2,295.3 million in FY2025 — 1.8% of the current market capitalisation — after nothing in FY2024 and $416.3 million in FY2023. Diluted shares fell from 362.7M to 358.5M between the FY2025 average and the June 2026 quarter. There is no dividend and none is indicated.

Two items that qualify the cash-flow picture. Stock-based compensation is $788.2 million, 7.8% of FY2025 revenue and 7.5% trailing — high in absolute terms and among the higher figures in this batch; it is a genuine cost that free cash flow does not deduct. And inventory of $1,840.0 million represents 201.4 days outstanding, up from $1,487.2M a year earlier — a large working-capital commitment for a company whose product is manufactured largely in Mexico and shipped into a shifting tariff regime.

5. Tariffs, which are the one genuinely new operating risk

The 10-Q's disclosure is unusually specific about both the exposure and the legal chaos around it:

> "changes in tariffs, trade barriers, and regulatory requirements (including changes to tariffs imposed by the U.S. on imports from various countries, including MEXICO, WHERE WE CURRENTLY MANUFACTURE A SIGNIFICANT MAJORITY OF OUR INSTRUMENTS AND ACCESSORIES, GERMANY, WHERE WE CURRENTLY MANUFACTURE A MAJORITY OF OUR ENDOSCOPES, and CHINA, where we currently import certain materials)"

Instruments and accessories are 59.8% of revenue and are manufactured mostly in Mexico. That is the single largest tariff exposure of any company in this batch.

And the regime itself changed twice in four months:

> "In February 2026, the U.S. Supreme Court ruled that these tariffs levied under the International Emergency Economic Powers Act ('IEEPA') were unlawful, because IEEPA does not authorize the President to impose tariffs. In response to the Supreme Court's ruling, a new 10% tariff for all imports under Section 122 of the Trade Act of 1974 was imposed. These tariffs took effect on February 24, 2026, and will remain in effect for 150 days, the maximum period that Section 122 permits without congressional action. The Section 122 tariffs have been challenged in the U.S. Court of International Trade; however, on June 11, 2026, the U.S. Court of Appeals for the Federal Circuit extended its stay of the lower court's ruling, keeping the 10% tariffs in place pending further proceedings."

An exclusion for goods originating under the United States-Mexico-Canada Agreement remains in place, which is the mitigating fact and the reason the impact is manageable. A refund process for the IEEPA tariffs already paid was opened by Customs and Border Protection on 20 April 2026.

Management's guidance quantifies the cost — management voice, half-weighted, and sourced from the knowledge base: non-GAAP gross margin of 67.5% to 68.5% for 2026, "including an estimated 1.0%-of-revenue adverse tariff impact." On approximately $11.8 billion of consensus FY2026 revenue that is roughly $118 million, or about $0.28 per share after tax — around 2.6% of the FY2026 consensus. Material but not thesis-changing, and the 150-day Section 122 clock means the position will change again before the year is out.

6. Valuation — priced in or room?

At $368.265 (market cap $130.10B, corrected enterprise value $124.47B):

Revenue coverage is outstanding — 25 to 26 analysts on every year through FY2029, the deepest in this batch — but EPS coverage collapses after FY2027: 16 and 17 analysts on FY2026 and FY2027, then 8 on FY2028 and 6 on FY2029. The FY2027 EPS range is $11.848 to $12.698, a 7.2% spread — extremely tight — which means the sell-side regards the earnings path as close to determined and the entire outcome distribution therefore sits in the multiple.

est.ebitdaAvg and est.ebitAvg are rejected. In every forward year ebitdaAvg is exactly 36.13% of revenueAvg and ebitAvg is exactly 30.27%, to four decimals — the fixed-ratio fabrication signature. Corroborating defect: netIncomeAvg exceeds ebitAvg in every forward year — $3,859M against $3,560M in FY2026, $4,311M against $4,018M in FY2027, $6,166M against $5,597M in FY2030 — which is arithmetically impossible. All forward valuation uses epsAvg and revenueAvg.

Peer context is unusable. The vendor peer set — Baxter, Becton Dickinson, Bionano Genomics, Cooper, Embecta, Hologic, ICU Medical, Innovative Eyewear, Merit Medical, NexGel, Repligen, ResMed, Stereotaxis, Teleflex, West Pharmaceutical — mixes a $130 billion franchise with several micro-capitalisation companies. No peer multiples are supplied in the file, so no peer-multiple comparison is drawn. Note that Stryker is in this batch and Medtronic — Intuitive's most credible large competitor — appears in the CVS and Danaher peer sets but not in Intuitive's own.

6a. What today's price assumes (the inversion)

At $368.265 — 34.1x FY2026 consensus and 30.5x FY2027 — the price embeds:

• Revenue of $11.76B in 2026 and $13.27B in 2027 — +16.8% then +12.9%. (Consensus; 25 analysts each.) The first half delivered $5,663.1M, so the second half needs $6,097.5M, a 7.7% sequential step. The nearest test is 2026-10-20 at a $2,906M consensus, +16.0% year on year.
• Worldwide procedure growth stays in the low-to-mid teens. (Our derivation; management guides 13.5-15.5%, half-weighted.) This is the most fragile assumption in the price. It has gone approximately 17% → 15% worldwide and approximately 14% → 12% in the United States in twelve months. A step to 10% would take FY2028 revenue roughly $1.0 billion below consensus and would almost certainly take the multiple with it.
• Non-GAAP gross margin holds near 67.5-68.5% including the roughly 1.0%-of-revenue tariff cost. (Management guidance, half-weighted.) The June quarter's GAAP gross margin of 67.8% is consistent. A material widening of the tariff exposure — the Section 122 authority expires after 150 days without congressional action — moves this either way.
• The market keeps paying roughly 30x or better on the forward year. (Our number.) At 25x FY2027E the stock is $302; at 40x it is $483. The multiple, not the earnings, is the whole variance — and this stock has already re-rated from north of 60x in twelve months, which is the single best evidence that multiples on this name can move a very long way.
• Competition does not become visible in placements or price. (Our number.) The 10-Q names "domestic competitors in certain geographic markets, such as China" and discloses a joint venture with Shanghai Fosun Pharmaceutical. Nothing in the reported numbers yet shows competitive damage; nothing in the reported numbers would show it early, either, because 75.4% of revenue is locked to the existing installed base.

6b. The return bridge (why the multiple moves)

Expected return over the next twelve months decomposes as: non-GAAP EPS growth (+11.9%, from FY2026E $10.798 to FY2027E $12.081) + multiple drift (EXPANSION required, from 30.5x to roughly 33x on the respective forward year, +8%) + shareholder yield (+1.8%, buyback only) ≈ +8% to +14%.

Our base case requires modest multiple expansion, and that is the fragile leg — we name it as such. At 30.5x forward for a business growing revenue 13% and earnings 12%, the price-to-earnings-to-growth ratio is roughly 2.5x. That is not cheap on any conventional screen. The argument for paying more is qualitative and it is the one this dive has spent five sections establishing: 75.4% recurring revenue, an installed base that only grows, an 86.4% equity ratio, no debt, and a switching cost measured in surgeon training rather than contract terms. The argument against is that the market has spent twelve months deciding exactly the opposite, and it has not finished.

Sensitivity: if the multiple simply HELD at 30.5x on FY2027E the price would be $368 — spot, exactly. At 27x it is $326; at 36x it is $435. A base case that needs the crowd to change its mind, on a stock in a fully established downtrend with no catalyst for 77 days, is a Watch by construction.

6c. Variant perception (where we differ, what would surprise)

• We differ from the street by 18.8%, DOWNWARD — $399 against $491.15 — and that is the widest disagreement in this batch. Thirty-nine of 57 analysts are at buy, with a consensus target implying 33.4% upside. When a stock has fallen 37.9% and the average analyst target is still a third above the price, the coverage is behind the market rather than ahead of it, and the low target of $357.44 — 3.0% BELOW spot — shows the dispersion. Five sell ratings, the most in this batch, are the more interesting datum.
• We differ from the vendor on enterprise value, in the company's favour. enterpriseValueTTM of $127.340B omits $2,566.9 million of short-term investments; the corrected figure is $124.468B, and on the widest definition net cash is $8,930.6 million, 6.9% of the market capitalisation. That is the KLAC-class omission and it makes every EV multiple in the payload roughly 2.3% too high.
• We think the international rollout is the under-modelled variable, in the positive direction. Of 1,710 da Vinci 5 systems installed, only 136 are outside the United States, despite European certification arriving in July 2025 and Japanese clearance in June 2025 — and outside-United-States procedures are growing approximately 20% against 12% domestically. The 32.3% of revenue growing at 20% is doing so with the current platform barely deployed. Watchable number: outside-United-States da Vinci 5 placements in the 2026-10-20 print. A move from 136 toward 250-300 would say the international leg is accelerating and would stabilise the blended growth rate without any United States improvement.
• We think the ACA subsidy expiration is the under-modelled variable in the negative direction. The 10-Q names it as a modest negative on United States procedure growth and says its continuing effect "remains uncertain." Two-thirds of revenue is the United States, and a policy change reducing insured elective-surgery volume is not something Intuitive can offset.
• Positive surprise that would force a re-rate: third-quarter worldwide procedure growth at or above 15% for a third consecutive quarter, which would say the deceleration has ended; a step-up in international da Vinci 5 placements; or an acceleration of the buyback beyond the FY2025 $2.3 billion pace into the drawdown.
• Negative surprise that would break the thesis: worldwide procedure growth below 13%, i.e. below management's own floor; United States growth below 10%; visible competitive share loss in system placements; a widening of the tariff impact beyond roughly 1.5% of revenue; or an inventory charge against the $1,840 million balance. Any of these hits a stock already 37.9% below its high with the 200-day average 23.5% overhead.

Synthos fair values

All three anchors are multiples of the FY2027 consensus non-GAAP EPS distribution (mean $12.081, low $11.848, high $12.698, 17 analysts) — the last year with adequate EPS coverage — cross-checked against FY2026E of $10.798 and FY2028E of $13.601.

• Bear ~$300 — 25.3x the FY2027 consensus LOW of $11.848. Cross-check: 27.8x FY2026E; 22.1x FY2028E; 9.6% BELOW the 52-week low of $332.02. The scenario: procedure growth steps to 10-11%, the ACA subsidy effect proves durable, competitors take visible share, tariffs widen, and the multiple completes its journey to a mature medical-device level. −18.5%.
• Base ~$399 — 33.0x the FY2027 consensus MEAN of $12.081. Cross-check: 37.0x FY2026E; 29.3x FY2028E; corrected enterprise value of $135.5B on FY2027E revenue of $13.27B is 10.2x sales. Sensitivity, stated openly: 30.5x — today's multiple, HELD — gives $368, which is spot exactly; 36x gives $435. The scenario: procedure growth stabilises in the mid-teens, the international rollout picks up, tariffs stay near 1% of revenue, and the market decides 30x was one step too far. +8.3%.
• Bull ~$570 — 44.9x the FY2027 consensus HIGH of $12.698. Cross-check: 41.9x FY2028E; 3.9% below the 52-week high of $592.85; 16.1% above the street's consensus target. The scenario: procedure growth reaccelerates on international deployment, the da Vinci 5 base outside the United States multiplies from 136, and the market re-rates a 75%-recurring franchise back toward where it traded a year ago. +54.8%.

Base is 8.3% above spot; asymmetry roughly 2.96:1 to the upside (18.5% down, 54.8% up) — the best payoff ratio in this batch. What keeps it a Watch rather than a Buy is that the base case requires the multiple to expand from 30.5x to 33x on a stock in a fully established downtrend, that the bear case at $300 sits below a 52-week low the stock touched recently, and that there is no company-specific event for 77 days.

7. Knowledge base — six hits, three of them the company itself

Raw hits: 6. Entity matches: 4. Independent name-level claims: 1. Management-voice claims excluded from the pool: 3. Homographs discarded: 1. Text-only sector claims: 1.

The sweep ran entity terms ISRG, Intuitive Surgical, Intuitive and da Vinci, plus free text on Intuitive Surgical, da Vinci, surgical robot and robotic surgery, across all 51,928 distilled claims.

The management channel — three claims, excluded from the conviction pool, retained as guidance

Three of the six hits come from a channel slug reading ISRG_mgmt. That is the company. It carries skill 0.5 — the lowest weight anywhere in this batch — which is the ingest layer correctly identifying and discounting a management source. All three are excluded from the conviction pool under the standing rule; all three are quoted here at half weight, and they are retained for a specific reason: the three 8-K filings in the ISRG archive are cover documents with the earnings releases unextracted, so this is the ONLY available source of the company's 2026 guidance.

> 2026-04-21 · bullish 78 · horizon: FACT · entities: ISRG, Intuitive Surgical · channel: ISRG_mgmt · skill 0.5

> "Guides full-year 2026 worldwide da Vinci procedure growth of approximately 13.5% to 15.5%."

> The June quarter delivered approximately 15% — at the top of the range.

> 2026-04-21 · neutral 65 · horizon: FACT · channel: ISRG_mgmt · skill 0.5

> "Expects 2026 non-GAAP gross margin of 67.5%–68.5%, including an estimated 1.0%-of-revenue adverse tariff impact."

> The June quarter's GAAP gross margin was 67.8%.

> 2026-04-21 · neutral 60 · horizon: FACT · channel: ISRG_mgmt · skill 0.5

> "Guides 2026 non-GAAP operating expense growth of 11% to 14%, signaling continued investment spend."

These are the most useful management-voice claims we have encountered in this programme, precisely because they are horizon FACT — quantified guidance rather than narrative — and because the filings independently corroborate the outcomes. They still do not constitute conviction, and none enters any score.

The homograph — discarded

> 2025-05-23 · forward_guidance · entities: Rocket Lab, INTUITIVE MACHINES — "Adding space names Rocket Lab and Intuitive Machines — lots of great things happening in the frontiers."

Intuitive Machines is a lunar-lander company. It is not Intuitive Surgical. Discarded. The entity sweep on "Intuitive" caught it; a sweep restricted to "Intuitive Surgical" would not have. This is the same class as "Amex Exploration" and "Chevron deference" recorded elsewhere in this programme.

The sector claim — retained as colour, not conviction

> 2024-08-01 · bullish 80 · thesis · no entities · channel: raoul_pal

> "Within 10-15 years humanoid surgical robots sharing pooled experience will be the best surgeons, and AI becomes everyone's diagnostician, democratizing healthcare."

Thematically relevant and ambiguous in sign. It validates robotic surgery as a direction while describing an architecture — humanoid, autonomous, learning from pooled experience — that is not what Intuitive builds. Intuitive's systems are teleoperated: a surgeon controls them in real time. A future in which the robot is the surgeon is not obviously Intuitive's future, and the claim names no company. Recorded, not scored.

The one independent claim

> 2025-09-18 · BULLISH · conviction 95 · thesis · entities: Amazon, Netflix, Nvidia, Tesla, Booking Holdings, Intuitive Surgical, MercadoLibre · channel: we_study_billionaires · no named speaker

> "These seven long-held names are his 100-baggers, still owned; buying and holding market leaders for 20+ years drove the returns."

Conviction 95 is the highest reading in this entire batch, and it must be read for what it is. It is a philosophy claim in a seven-name basket, attributed to a channel with no named speaker, dated eleven months ago and roughly 25% higher in price. It says nothing about valuation, about procedure growth, about tariffs or about the 38% drawdown. What it does say — and this is genuinely the long-run case — is that Intuitive Surgical belongs in the small set of businesses whose market leadership has compounded across two decades. We record it, we do not weight it heavily, and we note that a conviction-95 buy-and-hold claim is exactly the kind of signal that is least useful for deciding what to do in a drawdown.

Conclusion. Breadth 3, name-level independent claim count 1, net conviction positive-low. No concentration sensitivity test is meaningful across a lane in which half the claims are the company's own investor-relations output. The Synthos knowledge base regards Intuitive Surgical as a long-term compounder and has nothing whatsoever to say about it at $368.

8. Data integrity — what we rejected and why

Six findings. ISRG's file is among the cleanest in this batch: the segment and geographic tables both reconcile exactly, and the defects are confined to the enterprise value and the forward estimate rows.

1. enterpriseValueTTM omits $2,566.9M of short-term investments — REJECTED and rebuilt. The vendor reports $127.340B, computed as market capitalisation ($130.100B) plus total debt ($302.8M) less cash ($3,368.0M). It ignores $2,566.9 million of short-term investments. The corrected figure is $124.468B, a 2.3% reduction, and it moves evToSalesTTM from 11.54x to 11.28x. On the widest definition — counting the $3,298.5M of long-term investments — net cash is $8,930.6 million, 6.9% of the market capitalisation. This is the same defect class documented on KLA elsewhere in this programme.

2. est.ebitdaAvg and est.ebitAvg carry the fixed-ratio fabrication signature AND are arithmetically impossible — REJECTED. In every forward year ebitdaAvg is exactly 36.13% of revenueAvg and ebitAvg is exactly 30.27%. Additionally netIncomeAvg EXCEEDS ebitAvg in every forward year — $3,859M against $3,560M (FY2026), $4,311M against $4,018M (FY2027), $4,856M against $4,548M (FY2028), $6,166M against $5,597M (FY2030). Net income cannot exceed operating income for a company with a 17% tax rate and no material non-operating income. All forward valuation uses epsAvg and revenueAvg.

3. The FY2028 and FY2029 EPS rows rest on 8 and 6 analysts — used for context only. Revenue coverage is excellent throughout (25-26 analysts on every year), but EPS coverage falls from 17 on FY2027 to 8 on FY2028 and 6 on FY2029. No fair value is anchored beyond FY2027.

4. returnOnEquityTTM is NULL and epsdiluted is null in every income-statement row — worked around. Return on equity is computed here (trailing net income of $3,138.8M against average equity near $17.1B is approximately 18.4%); all per-share figures are computed and labelled, and cross-checked against the earn_cal non-GAAP actuals.

5. The peer set is not usable — REJECTED. Baxter, Becton Dickinson, Bionano Genomics, Cooper, Embecta, Hologic, ICU Medical, Innovative Eyewear, Merit Medical, NexGel, Repligen, ResMed, Stereotaxis, Teleflex and West Pharmaceutical. Four of the fifteen are micro-capitalisation companies offered as comparables for a $130 billion franchise, and Medtronic — Intuitive's most credible large competitor, and present in two other peer sets in this batch — is absent. No peer-multiple comparison is drawn.

6. The FY2025 gross-margin figure in inc_a differs slightly from the quarterly aggregation — noted, not material. inc_a FY2025 gross profit of $6,642.3M on revenue of $10,064.7M is 66.0%; the four constituent quarters aggregate to 66.4%. A 40 basis point difference from rounding in the quarterly series. Both are used and labelled; no conclusion turns on it.

Correct and worth recording — this file passes several tests that others in this batch fail: seg_prod sums to exactly $10,064.7M against reported FY2025 revenue of $10,064.7M, with three clean product lines and four years of history; seg_geo sums to exactly the same figure, with domestic and foreign lines and no omission (contrast DHR, where 40.6% of revenue is missing, and CB, where the block stops in 2014); bookValuePerShareTTM of $51.616 is correctly distinct from tangibleBookValuePerShareTTM of $46.762 — a $4.85 difference reflecting $381.4M of goodwill and intangibles; debtToEquityRatioTTM of 0 correctly reflects a near-debt-free balance sheet; stockBasedCompensationToRevenueTTM of 7.49% reconciles to $788.2M on $10,064.7M for FY2025; and quote.yearHigh/yearLow ($603.88/$328.57) sit within 1.9% and 1.0% of tech.hi52/lo52 ($592.85/$332.02), with tech used throughout.

Filing-archive limitation, stated plainly. The ISRG archive is flagged tables: false — filings extracted as prose without preserved statement tables — and all three 8-K filings are cover documents of 2,000 to 4,000 characters with the earnings releases unextracted. Consequently no management guidance figure is available from any filing, and the FY2026 guidance quoted in this dive (procedure growth 13.5-15.5%, non-GAAP gross margin 67.5-68.5%, operating expense growth 11-14%) comes from the knowledge base's ISRG_mgmt channel, labelled as management voice and half-weighted. The 10-Q's narrative disclosures — procedure growth by geography, installed base counts, tariff exposure and competitive risk — carried everything else this dive needed. All financial-statement figures come from the vendor payload.

Non-equity tripwire — checked and passed. ISRG is common stock, NASDAQ-listed. Price of $368.265 is not par-like; beta is 1.46; there is no dividend at all; volume was 3.84M shares (~$1.4B of turnover); the 52-week band of $332.02 to $592.85 is a 79% range. This is common equity.

9. Technicals — the most bearish configuration in this batch

• Price $368.265. −37.9% from the 52-week high of $592.85; only +10.9% above the 52-week low of $332.02. Position within the annual range: 14th percentile.
• Below both moving averages, and the averages are in the wrong order: −7.1% below a 50-day average of $396.49; −23.5% below a 200-day average of $481.23; and the 50-day is 17.6% BELOW the 200-day. This is the only fully bearish moving-average configuration in this batch.
• RSI 43.8 — weak, not oversold, which is itself notable after a 38% decline. MACD −12.25.
• Maximum drawdown from peak over the trailing year: −39.7%, against a current drawdown of −37.9%.
• Relative performance, and every horizon is negative: 3-month −18.6% against SPY +7.6% — a 26-point deficit in one quarter; 6-month −25.9% against SPY +11.1%; 12-month −23.8% against SPY +24.3% and QQQ +30.8% — a 48-point twelve-month deficit, the worst in this batch by a wide margin.
• Sentiment: 39 buy, 13 hold, 5 sell across 57 analysts — the most sell ratings in this batch; consensus target $491.15 (+33.4%), median $493.50, high $651 (+76.8%), low $357.44 — 3.0% BELOW spot. A consensus target a third above a stock that has fallen 38% is coverage lagging the market, and we treat it as such.

Today's move and what it does to the entry

ISRG closed 2026-08-04 at $368.265, down 1.90% or $7.145 from $375.41. It opened at $376.31 — the day's high — traded down to $364.26, and closed near the low on 3.84M shares. On a day most of this batch rose, Intuitive Surgical opened at its high and closed near its low. No company-specific filing is dated 2026-08-04; the last event was the 2026-07-16 earnings release, nineteen days earlier — a release that beat consensus by 12.9%.

The honest read: the stock is not responding to good news, and that is the single most important technical fact about it. A 12.9% earnings beat nineteen days ago has produced no bounce. Multiple compression of this kind ends when it ends, and there is no way to time it from the fundamentals.

What would change this:

• A price near $325-335 — roughly 27x FY2027E, at or just below the 52-week low of $332.02 — which would put our base $399 at a 19-23% premium and would represent a full de-rating to a mature medical-device multiple. That is 9-12% below today's close and the stock has traded there within the last twelve months.
• Or the 2026-10-20 print showing worldwide procedure growth at or above 15% for a third consecutive quarter, which would say the deceleration that caused the entire de-rating has stopped. At that point paying 30x is defensible, because the variable driving the multiple would have stabilised.

10. Insiders — a dribble and a routine exercise

The reading is short because there is very little here.

The chief executive's transactions are a routine option or unit exercise with tax settled by share withholding — 1,910 units converted, 947 shares withheld by the issuer at $411.55, recorded across two ownership lines. Not a sale. David Rosa retains 246,856 shares, worth approximately $90.9 million at today's close — a substantial, unhedged stake, and one that has lost roughly $35 million of value over the last twelve months on paper.

Mark Brosius sold exactly 28 shares on each of five consecutive trading days, totalling 140 shares for approximately $49,000, leaving 1,266. This is a pre-arranged trading plan executing in the smallest possible clips. At 140 shares it is not a signal about anything, and the residual holding of 1,266 shares is itself very small for an executive vice president.

What the file contains is therefore: zero meaningful open-market sales, zero purchases, and a chief executive whose holding is intact. Neutral, and reported as neutral. With the stock 38% below its high, the absence of any insider buying is a very mild negative — a management team convinced the market was wrong would have an obvious way to say so.

11. Verdict, kill-criteria and flip conditions

Watch.

What is genuinely excellent: a business where 75.4% of revenue is instruments, accessories and services billed against an installed base that only grows; a 66.7% gross margin and a June-quarter operating margin of 33.6%, the highest in the file; FY2025 revenue up 20.5% to $10,064.7M and June-quarter revenue up 18.5%; worldwide da Vinci procedures growing approximately 15%, at the top of management's own guided range; five consecutive earnings beats of 11.5% to 20.6%; roughly $9.2 billion of cash and investments against $302.8 million of mostly-lease debt, an 86.4% equity ratio and a debt-to-equity ratio of zero; $2,490.7 million of free cash flow and a $2,295.3 million buyback restarted into the drawdown; and an installed base of 1,710 da Vinci 5 systems with only 136 outside the United States, one year after European and Japanese clearance.

What holds it at Watch: 30.5x FY2027 consensus for 13% revenue growth and 12% earnings growth — a price-to-earnings-to-growth ratio of roughly 2.5x; a base case that REQUIRES the multiple to expand from 30.5x to 33x, on a stock in the only fully bearish moving-average configuration in this batch, with the 200-day average 23.5% overhead and the 50-day 17.6% below it; a 48-point twelve-month underperformance that a 12.9% earnings beat nineteen days ago failed to arrest; procedure growth decelerating from approximately 17% to 15% worldwide and 14% to 12% in the United States, with the company naming an ACA subsidy expiration whose continuing effect "remains uncertain"; a significant majority of instruments manufactured in Mexico into a tariff regime that changed twice in four months; no dividend; a street target 33.4% above a stock that has fallen 38%, which is coverage lagging price; and a knowledge-base lane in which half the claims are the company's own guidance and one is a lunar-lander company.

The distinction that matters. This is not a call that Intuitive Surgical is a poor business — it is the second-best business in this batch on quality, behind Chubb, and it is the best on growth. It is a call that a 38% de-rating driven by a two-point deceleration in the growth rate has not obviously finished, that our own base case needs the multiple to turn before it works, and that there is no company-specific event for 77 days to make it turn. In the Synthos frame, a name with a 2.96:1 payoff ratio whose base case depends on multiple expansion is a Watch with a specific price attached — roughly $325 — and a specific event that would substitute for it, namely a third consecutive quarter of procedure growth at or above 15%.

Pre-registered KILL criteria — what would take this to Avoid:

• Worldwide da Vinci procedure growth below 13%, i.e. below the floor of management's own 13.5-15.5% guidance, in any quarter.
• United States procedure growth below 10%, which would say the ACA subsidy effect or general-surgery saturation is structural rather than transient.
• Visible competitive share loss — a decline in system placements, or any disclosure of pricing pressure from Medtronic, Johnson & Johnson or the Chinese domestic competitors the 10-Q names.
• Non-GAAP gross margin below 66%, or a tariff impact above roughly 1.5% of revenue, which would mean the Mexican and German manufacturing footprint has become a structural cost rather than a manageable one.
• An inventory charge against the $1,840 million balance, at 201 days outstanding.
• A break below the 52-week low of $332.02 on company-specific news rather than market beta.

Pre-registered FLIP conditions — what would take this to Buy — Tactical:

• A price in the $325-335 band — roughly 27x FY2027E, at or just below the 52-week low — with the fundamentals intact. This is the single most likely path to a Buy and it is only 9-12% below today's close.
• The 2026-10-20 print showing worldwide procedure growth at or above 15% for a third consecutive quarter, which would say the deceleration driving the entire de-rating has ended.
• Outside-United-States da Vinci 5 placements moving materially above 136, which would convert the international rollout from an assertion into a number and would stabilise blended growth without any United States improvement.
• An acceleration of the buyback beyond the FY2025 $2.3 billion pace, which at a 38% discount to the prior high would be a genuine capital-allocation signal.
• A reclaim of the 50-day moving average at $396.49, which would be the first evidence the downtrend has broken — a technical flip only, and it would need one of the fundamental legs with it.

Where ISRG fits in the Synthos Framework Portfolio. The medical-technology sleeve, at 0% today with a 2-3% target on a fill in the $325-335 band or a confirming October print. On batch overlap: SYK and DHR are also in this batch and all three appear in each other's or in adjacent peer sets — but the exposures are distinct. Danaher sells consumables into laboratories, Stryker sells implants and capital equipment into orthopaedic theatres, and Intuitive sells a platform plus its consumables into general surgery. Of the three, Intuitive has by far the highest recurring-revenue share and by far the worst twelve-month price performance, which is precisely the combination that makes it the most interesting of them at the right entry. Logged as a tracked Synthos call (Watch) as of 2026-08-04 at $368.265.

Single biggest risk: procedure growth keeps decelerating. It has gone from approximately 17% to approximately 15% worldwide and from approximately 14% to approximately 12% in the United States in twelve months, and the 10-Q attributes part of the United States slowdown to a policy change — the expiration of enhanced ACA premium subsidies — whose continuing effect the company says "remains uncertain." Because 75.4% of revenue is consumed per procedure, the procedure growth rate IS the revenue growth rate over any period longer than a quarter. A step to 10% would take FY2028 revenue roughly a billion dollars below consensus and would almost certainly take the multiple with it — and this stock has just demonstrated, over twelve months and 38 percentage points, exactly how far its multiple can travel when the growth rate moves two points. That is the $300 bear case, and it requires no competitive disaster, no regulatory event and no execution failure — only for the last two years' trend to continue.

Provenance & disclosures

• Traceability: 1 independent tagged knowledge-base claim names Intuitive Surgical out of 51,928 distilled claims (raw hits 6, entity matches 4, management-voice claims EXCLUDED from the pool 3, homographs discarded 1, text-only sector claims 1; breadth 3, net conviction positive-low). THREE of the six hits come from a channel slug reading ISRG_mgmt — the company itself — carrying skill 0.5, the lowest weight anywhere in this batch, which is the ingest layer correctly identifying and discounting a management source. All three are dated 2026-04-21, are horizon FACT, and carry the company's 2026 guidance: worldwide da Vinci procedure growth of approximately 13.5% to 15.5% (conviction 78), non-GAAP gross margin of 67.5%–68.5% including an estimated 1.0%-of-revenue adverse tariff impact (conviction 65), and non-GAAP operating expense growth of 11% to 14% (conviction 60). They are excluded from the conviction pool and quoted at half weight — and retained as the ONLY available source of the company's 2026 guidance, because all three 8-K filings in this archive are cover documents with the earnings releases unextracted. ONE discard is a homograph: forward_guidance 2025-05-23 names Rocket Lab and INTUITIVE MACHINES, a lunar-lander company, caught by an entity sweep on "Intuitive". ONE is a text-only sector claim: raoul_pal 2024-08-01 (conviction 80) that within 10-15 years "humanoid surgical robots sharing pooled experience will be the best surgeons" — thematically relevant, ambiguous in sign, describing an architecture Intuitive does not build (its systems are teleoperated), and naming no company; recorded, not scored. That leaves exactly ONE independent entity-matched claim: we_study_billionaires 2025-09-18, conviction 95 — the highest reading in this batch — naming Intuitive Surgical among seven "100-baggers, still owned" on a buy-and-hold philosophy. It is a seven-name basket claim with no named speaker, eleven months old and struck roughly 25% higher, and it says nothing about valuation, procedure growth or the drawdown. No concentration sensitivity test is meaningful across a lane in which half the claims are the company's own investor-relations output. All quotes are verbatim from the stored claim text.
• Data as-of: fundamentals — procedure growth, installed-base counts, tariff exposure and competitive disclosure through 2026-06-30, filing-verified from the 10-Q filed 2026-07-21; financial-statement figures from the vendor payload for the reason set out below · estimates 2026-08-04 · prices 2026-08-04, quote timestamp 1785873601 = 2026-08-04T20:00:01Z ($368.265, −1.90%; 50-DMA $396.49; 200-DMA $481.23; RSI 43.8; MACD −12.25) · knowledge-base claims 2026-08-04. Intuitive Surgical's fiscal year is the calendar year. All figures come from the Synthos vendor data file for ISRG or from the SEC filings in the ISRG archive; no figure comes from memory, recall or external retrieval.
• Filing archive contents and its limitation: 10-K filed 2026-02-03 (fiscal 2025); 10-Q filed 2026-04-22 (March 2026 quarter); 10-Q filed 2026-07-21 (June 2026 quarter — the source of every filing-verified operational figure in this dive); 8-K filed 2026-05-28; 8-K filed 2026-07-16 (second-quarter results); 8-K filed 2026-07-27. The archive is flagged tables: false — filings extracted as prose without preserved statement tables — and ALL THREE 8-K filings are cover documents of 2,000 to 4,000 characters with the earnings releases unextracted. Consequently NO management guidance figure is available from any filing, and the FY2026 guidance quoted here comes from the knowledge base's ISRG_mgmt channel, labelled as management voice and half-weighted. The 10-Q's narrative carried procedure growth by geography, installed-base counts, the tariff disclosure and the competitive risk factors. All financial-statement figures come from the vendor payload, cross-checked against the earn_cal non-GAAP actuals.
• Where the filings supplied what the vendor could not, and where the vendor was wrong (detailed in Section 8): enterpriseValueTTM of $127.340B omits $2,566.9M of short-term investments — the corrected figure is $124.468B, a 2.3% reduction, moving evToSalesTTM from 11.54x to 11.28x, and on the widest definition net cash is $8,930.6M or 6.9% of market capitalisation; est.ebitdaAvg/ebitAvg rejected for a fixed-ratio signature (exactly 36.13% and 30.27% of revenue in every forward year) and for netIncomeAvg exceeding ebitAvg in EVERY forward year, which is impossible for a company with a 17% tax rate; returnOnEquityTTM is NULL and is computed here at approximately 18.4%; epsdiluted is null in every income-statement row; and the peer set is rejected for containing four micro-capitalisation companies (Bionano Genomics, Innovative Eyewear, NexGel, Stereotaxis) as comparables for a $130 billion franchise while omitting Medtronic. Procedure growth by geography, the 1,710 / 136 / 445 installed-base counts, the Mexico and Germany manufacturing concentration, the Section 122 tariff position and the Chinese-competitor disclosure appear in NO vendor field. Where vendor and filing AGREED — recorded because these defect classes usually bite: seg_prod sums to EXACTLY $10,064.7M against reported FY2025 revenue of $10,064.7M with three clean product lines and four years of history; seg_geo sums to exactly the same figure with no omission; bookValuePerShareTTM of $51.616 correctly distinct from tangibleBookValuePerShareTTM of $46.762; debtToEquityRatioTTM of 0 correctly reflecting a near-debt-free balance sheet; and quote versus tech 52-week ranges within 1.9%.
• Basis note: the earn_cal "actual" EPS figures are non-GAAP — trailing non-GAAP EPS across the four reported quarters is $10.53 against trailing GAAP EPS of $8.85, a 19.0% gap driven principally by stock-based compensation at 7.5% of revenue. Analyst estimates are on the non-GAAP basis and all forward multiples in this dive use it; the trailing multiple is shown on both (35.0x non-GAAP, 41.6x GAAP) and labelled. Stock-based compensation of $788.2M in FY2025 is a real cost that neither the non-GAAP earnings figure nor the free-cash-flow figure deducts, and it is flagged in Section 4 for that reason.
• Estimate coverage: 25-26 analysts on revenue for every year through FY2029 — the deepest revenue coverage in this batch — but EPS coverage falls sharply: 16 on FY2026, 17 on FY2027 (the anchor for all three fair values, with a range of $11.848 to $12.698, a 7.2% spread), 8 on FY2028 and 6 on FY2029, both of which are shown for context and carry no fair value.
• Peer note: the vendor peer set — Baxter, Becton Dickinson, Bionano Genomics, Cooper, Embecta, Hologic, ICU Medical, Innovative Eyewear, Merit Medical, NexGel, Repligen, ResMed, Stereotaxis, Teleflex, West Pharmaceutical — contains four micro-capitalisation names and omits Medtronic, Intuitive's most credible large competitor, which appears in two other peer sets in this batch. No peer-multiple comparison is drawn.
• Fair-value caveat: the $300 / $399 / $570 anchors are multiples of the FY2027 consensus non-GAAP EPS distribution — 25.3x the low of $11.848, 33.0x the mean of $12.081, and 44.9x the high of $12.698. Stated arithmetic, not a discounted cash flow. The base is sensitivity-disclosed: 30.5x — today's multiple, HELD — gives $368, which is spot EXACTLY; 36x gives $435. The base case therefore REQUIRES modest multiple expansion, on a stock in a fully established downtrend — that is the fragile leg and it is named as such in the return bridge and in the verdict. Note also that the bear case at $300 sits 9.6% below the 52-week low of $332.02.
• Management-voice note: the FY2026 guidance (worldwide procedure growth 13.5-15.5%, non-GAAP gross margin 67.5-68.5% including an approximately 1.0%-of-revenue tariff impact, non-GAAP operating expense growth 11-14%) is management's own claim, sourced from a management channel, and half-weighted throughout, labelled wherever quoted. It is used because no filing in this archive carries guidance.
• Timing: second-quarter 2026 results were released 2026-07-16, nineteen days before this dive, beating the consensus non-GAAP EPS estimate by 12.9% ($2.80 against $2.48) — the fifth consecutive beat. The next print is 2026-10-20, 77 days away. 2026-08-04 carried no company-specific filing; the stock opened at the day's high and closed near the low, down 1.90%, on a day most of this batch rose.
• Accessibility note: no information in this dive is conveyed by colour. All emphasis is carried by bold text, table structure and explicit labelling.
• Not investment advice. Independent research, educational and informational only, never personalised. No recommendation to buy, sell or hold any security is made to any person.
• Version: 2026-08-04-full.